Answers are grounded in this paper and cite their sources.
Summary Sickle cell disease (SCD) is a thrombophilia exacerbated by pregnancy. However, there is not strong evidence for thromboprophylaxis, perhaps because most data addressing pregnancy‐related thrombosis in SCD is limited by derivation from administrative datasets. We studied venous thromboembolism (VTE) in a retrospective cohort of pregnant people with SCD who delivered singleton pregnancies at two academic centres between 1990 and 2021. Among 289 pregnancies to 197 SCD subjects, 6% had VTE. We compared characteristics of the first study pregnancy in which a VTE occurred (cases) to the first study pregnancy in subjects without pregnancy‐related VTE (controls). Preconception complications associated with VTE were history of VTE (cases: 33% [ n = 5/15] vs. controls: 4% [ n = 7/182], p < 0.001), acute chest syndrome (ACS) (80% [ n = 12/15] vs. 37% [ n = 68/182], p = 0.001) and acute care for vaso‐occlusive crisis (VOC) in the year before pregnancy (80% [ n = 12/15] vs. 43% [ n = 70/182], p = 0.006). Prenatal complications associated with VTE were ACS (47% [ n = 7/15] vs. 10% [ n = 19/182], p < 0.001) and VOC (93% [ n = 14/15] vs. 65% [ n = 119/182], p = 0.026). Fetal outcomes associated with VTE included gestational age at delivery (median [IQR] 37.0 [34.0–38.1] weeks vs. 38.3 [36.9–39.3], p = 0.004). Studies are needed to establish interventions that attenuate VTE risk and define prophylactic anti‐coagulation parameters for this high‐risk population.
No takes yet. Share an insight, caveat, or question.
Gerber et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: